Nutrition
Volume 22, Issue 1 , Pages 36-46 , January 2006

Bioavailability and safety of a high dose of docosahexaenoic acid triacylglycerol of algal origin in cystic fibrosis patients: a randomized, controlled study

  • John D. Lloyd-Still, M.D.

      Affiliations

    • Rush University Medical Center, Chicago, Illinois, USA
    • Corresponding Author InformationCorresponding author. Tel.: +312-563-2132; fax: +312-563-2131
    • ,
  • Catherine A. Powers, R.D.

      Affiliations

    • Rush University Medical Center, Chicago, Illinois, USA
    • ,
  • Dennis R. Hoffman, Ph.D.

      Affiliations

    • Retina Foundation of the Southwest, Dallas, Texas, USA
    • ,
  • Katherine Boyd-Trull, B.S.

      Affiliations

    • Retina Foundation of the Southwest, Dallas, Texas, USA
    • ,
  • Lucille A. Lester, M.D.

      Affiliations

    • Rush University Medical Center, Chicago, Illinois, USA
    • ,
  • Diane C. Benisek, R.D.

      Affiliations

    • Martek Biosciences Corp., Columbia, Maryland, USA
    • ,
  • Linda M. Arterburn, Ph.D.

      Affiliations

    • Martek Biosciences Corp., Columbia, Maryland, USA

Received 20 November 2004 ,Accepted 23 May 2005.

References 

  1. Benabdeslam H , Garcia I , Bellon G , Gilly R , Revol A . Biochemical assessment of the nutritional status of cystic fibrosis patients treated with pancreatic enzyme extracts . Am J Clin Nutr . 1998;67:912–918
  2. Roulet M , Frascarolo P , Rappaz I , Pilet M . Essential fatty acid deficiency in well nourished young cystic fibrosis patients . Eur J Pediatr . 1997;156:952–956
  3. Lloyd-Still JD , Bibus DM , Powers CA , Johnson SB , Holman RT . Essential fatty acid deficiency and predisposition to lung disease in cystic fibrosis . Acta Paediatr . 1996;85:1426–1432
  4. Clandinin MT , Zuberbuhler P , Brown NE , Kielo ES , Goh YK . Fatty acid pool size in plasma lipoprotein fractions of cystic fibrosis patients . Am J Clin Nutr . 1995;62:1268–1275
  5. Christophe AB , Warwick WJ , Holman RT . Serum fatty acid profiles in cystic fibrosis patients and their parents . Lipids . 1994;29:569–575
  6. Lloyd-Still JD , Johnson SB , Holman RT . Essential fatty acid status and fluidity of plasma phospholipids in cystic fibrosis infants . Am J Clin Nutr . 1991;54:1029–1035
  7. Farrell PM , Mischler EH , Engle MJ , Brown DJ , Lau SM . Fatty acid abnormalities in cystic fibrosis . Pediatr Res . 1985;19:104–109
  8. Underwood B , Denning C , Navab M . Polyunsaturated fatty acids and tocopherol levels in patients with cystic fibrosis . Ann NY Acad Sci . 1972;203:237–247
  9. Strandvik B . Fatty acid metabolism in cystic fibrosis . N Engl J Med . 2004;350:605–607
  10. Kang JX , Man SF , Brown NE , Labrecque PA , Clandinin MT . The chloride channel blocker anthracene 9-carboxylate inhibits fatty acid incorporation into phospholipid in cultured human airway epithelial cells . Biochem J . 1992;285(pt 3):725–729
  11. Craig-Schmidt MC , Faircloth SA , Teer PA , Weete JD , Wu CY . The essential fatty acid deficient chicken as a model for cystic fibrosis . Am J Clin Nutr . 1986;44:816–824
  12. Harper TB , Chase HP , Henson J , Henson PM . Essential fatty acid deficiency in the rabbit as a model of nutritional impairment in cystic fibrosis (In vitro and in vivo effects on lung defense mechanisms) . Am Rev Respir Dis . 1982;126:540–547
  13. Freedman SD , Katz MH , Parker EM , Laposata M , Urman MY , Alvarez JG . A membrane lipid imbalance plays a role in the phenotypic expression of cystic fibrosis in cftr(−/−) mice . Proc Natl Acad Sci USA . 1999;96:13995–14000
  14. Gibson RA , Teubner JK , Haines K , Cooper DM , Davidson GP . Relationships between pulmonary function and plasma fatty acid levels in cystic fibrosis patients . J Pediatr Gastroenterol Nutr . 1986;5:408–415
  15. Werner A , Bongers ME , Bijvelds MJ , de Jonge HR , Verkade HJ . No indications for altered essential fatty acid metabolism in two murine models for cystic fibrosis . J Lipid Res . 2004;45:2277–2286
  16. Dombrowsky H , Clark GT , Rau GA , Bernhard W , Postle AD . Molecular species compositions of lung and pancreas phospholipids in the cftr(tm1HGU/tm1HGU) cystic fibrosis mouse . Pediatr Res . 2003;53:447–454
  17. Thies NH . The effect of 12 months’ treatment with eicosapentaenoic acid in five children with cystic fibrosis . J Paediatr Child Health . 1997;33:349–351
  18. Katz DP , Manner T , Furst P , Askanazi J . The use of an intravenous fish oil emulsion enriched with omega-3 fatty acids in patients with cystic fibrosis . Nutrition . 1996;12:334–339
  19. Kurlandsky LE , Bennink MR , Webb PM , Ulrich PJ , Baer LJ . The absorption and effect of dietary supplementation with omega-3 fatty acids on serum leukotriene B4 in patients with cystic fibrosis . Pediatr Pulmonol . 1994;18:211–217
  20. Henderson WR , Astley SJ , McCready MM , Kushmerick P , Casey S , Becker JW , et al.   Oral absorption of omega-3 fatty acids in patients with cystic fibrosis who have pancreatic insufficiency and in healthy control subjects . J Pediatr . 1994;124:400–408
  21. Lawrence RH , Sorrell TC . Eicosapentaenoic acid modulates neutrophil leukotriene B4 receptor expression in cystic fibrosis . Clin Exp Immunol . 1994;98:12–16
  22. Lawrence R , Sorrell T . Eicosapentaenoic acid in cystic fibrosis (evidence of a pathogenetic role for leukotriene B4) . Lancet . 1993;342(8869):465–469
  23. Christophe A , Robberecht E , De Baets F , Franckx H . Increase of long chain omega-3 fatty acids in the major serum lipid classes of patients with cystic fibrosis . Ann Nutr Metab . 1992;36:304–312
  24. Benisek D, Bailey-Hall E, Oken H, Masayesva S, Arterburn L. Validation of a simple food frequency questionnaire as an indicator of long chain omega-3 intake. In: Inform 2002. Abstracts of the 93rd Annual AOCS Meeting and Expo, AOCS Press, Champaign, IL 2002.
  25. Bligh EG , Dyer WJ . A rapid method of total lipid extraction and purification . Can J Biochem Physiol . 1954;37:911–917
  26. Morrison WR , Smith LM . Preparation of fatty acid methyl esters and dimethylacetals from lipids with boron fluoride-methanol . J Lipid Res . 1964;5:600–608
  27. Hoffman DR , Birch EE , Birch DG , Uauy R , Castaneda YS , Lapus MG , et al.   Impact of early dietary intake and blood lipid composition of long-chain polyunsaturated fatty acids on later visual development . J Pediatr Gastroenterol Nutr . 2000;31:540–553
  28. Epler KS , Ziegler RG , Craft NE . Liquid chromatographic method for the determination of carotenoids, retinoids and tocopherols in human serum and in food . J Chromatogr . 1993;619:37–48
  29. Agren JJ , Hanninen O , Julkunen A , Fogelholm L , Vidgren H , Schwab U , et al.   Fish diet, fish oil and docosahexaenoic acid rich oil lower fasting and postprandial plasma lipid levels . Eur J Clin Nutr . 1996;50:765–771
  30. Innis SM , Hansen JW . Plasma fatty acid responses, metabolic effects, and safety of microalgal and fungal oils rich in arachidonic and docosahexaenoic acids in healthy adults . Am J Clin Nutr . 1996;64:159–167
  31. Wheaton DH , Hoffman DR , Locke KG , Watkins RB , Birch DG . Biological safety assessment of docosahexaenoic acid supplementation in a randomized clinical trial for X-linked retinitis pigmentosa . Arch Ophthalmol . 2003;121:1269–1278
  32. Nelson GJ , Schmidt PC , Bartolini GL , Kelley DS , Kyle D . The effect of dietary docosahexaenoic acid on plasma lipoproteins and tissue fatty acid composition in humans . Lipids . 1997;32:1137–1146
  33. Christophe AB , Holman RT . Diet and EFA status in cystic fibrosis patients . Inform . 1992;3:449–455
  34. Lloyd-Still JD , Johnson SB , Holman RT . Essential fatty acid status in cystic fibrosis and the effects of safflower oil supplementation . Am J Clin Nutr . 1981;34:1–7
  35. Freedman SD , Blanco PG , Zaman MM , Shea JC , Ollero M , Hopper IK , et al.   Association of cystic fibrosis with abnormalities in fatty acid metabolism . N Engl J Med . 2004;350:560–569
  36. Keicher U , Koletzko B , Reinhardt D . Omega-3 fatty acids suppress the enhanced production of 5-lipoxygenase products from polymorph neutrophil granulocytes in cystic fibrosis . Eur J Clin Invest . 1995;25:915–919
  37. Kelley DS , Taylor PC , Nelson GJ , Schmidt PC , Ferretti A , Erickson KL , et al.   Docosahexaenoic acid ingestion inhibits natural killer cell activity and production of inflammatory mediators in young healthy men . Lipids . 1999;34:317–324
  38. Freedman SD , Weinstein D , Blanco PG , Martinez-Clark P , Urman S , Zaman M , et al.   Characterization of LPS-induced lung inflammation in cftr(−/−) mice and the effect of docosahexaenoic acid . J Appl Physiol . 2002;92:2169–2176
  39. Greener M . Fatty acid imbalance might lead to novel treatments for CF . Mol Med Today . 2000;6:47–48
  40. Institute of Medicine of the National Academies . Dietary reference intakes (energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein, and amino acids) . Washington, DC: National Academies Press; 2002;
  41. Henderson WR , Astley SJ , Ramsey BW . Liver function in patients with cystic fibrosis ingesting fish oil . J Pediatr . 1994;125:504–505
  42. Carlson SE , Werkman SH , Peeples JM , Cooke RJ , Tolley EA . Arachidonic acid status correlates with first year growth in preterm infants . Proc Natl Acad Sci USA . 1993;90:1073–1077
  43. Linsdell P . Inhibition of cystic fibrosis transmembrane conductance regulator chloride channel currents by arachidonic acid . Can J Physiol Pharmacol . 2000;78:490–499
  44. Winklhofer-Roob BM . Cystic fibrosis (nutritional status and micronutrients) . Curr Opin Clin Nutr Metab Care . 2000;3:293–297
  45. Winklhofer-Roob B . Impaired antioxidant status and increased lipid peroxidation in cystic fibrosis . Pediatr Pulmon . 1998;17:140–141
  46. Winklhofer-Roob B , van’t Hof M , Shmerling D . Response to oral beta-carotene supplementation in patients with cystic fibrosis (a 16-month follow-up study) . Acta Paediatr . 1995;84:1132–1136
  47. Homnick D , Cox J , DeLoof M , Ringer T . Carotenoid levels in normal children and in children with cystic fibrosis . J Pediatr . 1993;122(5 pt 1):703–707
  48. Huet F , Semama D , Maingueneau C , Charavel A , Nivelon J . Vitamin A deficiency and nocturnal vision in teenagers with cystic fibrosis . Eur J Pediatr . 1997;156:949–951
  49. Madarasi A , Lugassi A , Greiner E , Holics K , Biro L , Mozsary E . Antioxidant status in patients with cystic fibrosis . Ann Nutr Metab . 2000;44:207–211
  50. Kawchak D , Sowell A , Hofley P , Zemel B , Scanlin T , Stallings V . Longitudinal analysis shows serum carotenoid concentrations are low in children with cystic fibrosis . J Am Diet Assoc . 1999;99:1569–1572
  51. Semba R , Dagnelie G . Are lutein and zeaxanthin conditionally essential nutrients for eye health? . Med Hypotheses . 2003;61:465–472
  52. Colombo C , Apostolo M , Ferrari M , Seia M , Genoni S , Giunta A , et al.   Analysis of risk factors for the development of liver disease associated with cystic fibrosis . J Pediatr . 1994;124:393–399

 This study was funded by Martek Biosciences Corporation, Columbia, Maryland, USA.

PII: S0899-9007(05)00231-5

doi: 10.1016/j.nut.2005.05.006

Nutrition
Volume 22, Issue 1 , Pages 36-46 , January 2006

Article Tools